{"id":151469,"date":"2022-11-29T23:24:04","date_gmt":"2022-11-30T05:24:04","guid":{"rendered":"https:\/\/lifeboat.com\/blog\/2022\/11\/rare-success-for-alzheimers-research-unlocks-hope-for-future-therapies"},"modified":"2022-11-29T23:24:04","modified_gmt":"2022-11-30T05:24:04","slug":"rare-success-for-alzheimers-research-unlocks-hope-for-future-therapies","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2022\/11\/rare-success-for-alzheimers-research-unlocks-hope-for-future-therapies","title":{"rendered":"Rare success for Alzheimer\u2019s research unlocks hope for future therapies"},"content":{"rendered":"<p><a class=\"aligncenter blog-photo\" href=\"https:\/\/lifeboat.com\/blog.images\/rare-success-for-alzheimers-research-unlocks-hope-for-future-therapies2.jpg\"><\/a><\/p>\n<p>CHICAGO, Nov 29 (Reuters) \u2014 The first big breakthrough in 30 years of Alzheimer\u2019s research is providing momentum for clinical trials of \u201ccocktail\u201d treatments targeting the two hallmark proteins associated with the mind-robbing disease, according to interviews with researchers and pharmaceutical executives.<\/p>\n<p>Drugmakers Eisai Co Ltd <a data-testid=\"Link\" href=\"https:\/\/www.reuters.com\/companies\/4523.T\" target=\"_blank\" class=\"\">(4523.T)<\/a> and Biogen <a data-testid=\"Link\" href=\"https:\/\/www.reuters.com\/companies\/BIIB.O\" target=\"_blank\" class=\"\">(BIIB.O)<\/a><\/p>\n<p>Reported in September that their therapy lecanemab could slow progress of the disease by 27% over 18 months compared with a placebo [<a data-testid=\"Link\" href=\"https:\/\/www.reuters.com\/business\/healthcare-pharmaceuticals\/eisai-says-alzheimers-drug-succeeds-slowing-cognitive-decline-2022-09-27\/\" class=\"\"> read more<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>CHICAGO, Nov 29 (Reuters) \u2014 The first big breakthrough in 30 years of Alzheimer\u2019s research is providing momentum for clinical trials of \u201ccocktail\u201d treatments targeting the two hallmark proteins associated with the mind-robbing disease, according to interviews with researchers and pharmaceutical executives. Drugmakers Eisai Co Ltd (4523.T) and Biogen (BIIB.O) Reported in September that their [\u2026]<\/p>\n","protected":false},"author":359,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11,47],"tags":[],"class_list":["post-151469","post","type-post","status-publish","format-standard","hentry","category-biotech-medical","category-neuroscience"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/151469","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/359"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=151469"}],"version-history":[{"count":0,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/151469\/revisions"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=151469"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=151469"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=151469"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}